| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3321 | 2014 |
| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 771 | 2018 |
| Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Prostate Cancer Trialists Collaborative Group The Lancet 355 (9214), 1491-1498, 2000 | 541 | 2000 |
| A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ... Nature genetics 46 (10), 1103-1109, 2014 | 521 | 2014 |
| Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup P Iversen, CJ Tyrrell, AV Kaisary, JB ANDERSON, H Van Poppel, ... The Journal of urology 164 (5), 1579-1582, 2000 | 504 | 2000 |
| Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 438 | 2017 |
| A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate … CJ Tyrrell, AV Kaisary, P Iversen, JB Anderson, L Baert, T Tammela, ... European urology 33 (5), 447-456, 1998 | 421 | 1998 |
| Climate instability during the last interglacial period recorded in the GRIP ice core Greenland Ice-core Project (GRIP) Members Nature 364 (6434), 203-207, 1993 | 399 | 1993 |
| Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer DG McLEOD, P Iversen, WA See, T Morris, JON Armstrong, MP Wirth, ... BJU international 97 (2), 247-254, 2006 | 385 | 2006 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 309 | 2021 |
| Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early … WA See, MP Wirth, DG McLeod, P Iversen, I Klimberg, D Gleason, ... The Journal of urology 168 (2), 429-435, 2002 | 284 | 2002 |
| Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early … WA See, MP Wirth, DG McLeod, P Iversen, I Klimberg, D Gleason, ... The Journal of urology 168 (2), 429-435, 2002 | 282 | 2002 |
| A point system for selecting operative candidates PO Madsen, P Iversen Benign prostatic hypertrophy, 763-765, 1983 | 280 | 1983 |
| Active surveillance for clinically localized prostate cancer––A systematic review FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen Journal of surgical oncology 109 (8), 830-835, 2014 | 242 | 2014 |
| Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer … MP Wirth, WA See, DG McLEOD, P Iversen, T Morris, K Carroll, ... The Journal of urology 172 (5), 1865-1870, 2004 | 240 | 2004 |
| Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized … P Iversen, CJ Tyrrell, AV Kaisary, JB Anderson, L Baert, T Tammela, ... Urology 51 (3), 389-396, 1998 | 221 | 1998 |
| Value of postvoid residual urine determination in evaluation of prostatism RC Bruskewitz, P Iversen, PO Madsen Urology 20 (6), 602-604, 1982 | 195 | 1982 |
| Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts TM Seibert, CC Fan, Y Wang, V Zuber, R Karunamuni, JK Parsons, ... bmj 360, 2018 | 178 | 2018 |
| Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer ML Huber, L Haynes, C Parker, P Iversen Journal of the National Cancer Institute 104 (4), 273-279, 2012 | 173 | 2012 |
| Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer ML Huber, L Haynes, C Parker, P Iversen Journal of the National Cancer Institute 104 (4), 273-279, 2012 | 173 | 2012 |
Klaus BrassoCopenhagen Prostate Cancer Center, Rigshospitalet.Bestätigte E-Mail-Adresse bei regionh.dk
